As of Apr 28
| -0.05 / -3.13%|
The 3 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 6.00, with a high estimate of 7.00 and a low estimate of 2.00. The median estimate represents a +287.10% increase from the last price of 1.55.
The current consensus among 6 polled investment analysts is to Hold stock in Regulus Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.